NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025

Award

Buyers

NHS England

Value

£4,108,145,000

Suppliers

Classifications

Pharmaceutical products

Submission Deadline

3 months ago

Published

1 day ago

Description

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement:  01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement:  01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Documents

Premium

Bypass the hassle of outdated portals. Get all the information you need right here, right now.

Contract Agreement

The official contract terms, conditions, and scopes of work.

Download
Award Notice

Details on the tender award and selected suppliers.

Download